Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Nature represents a rich source of compounds used for the treatment of many diseases.
Camptothecin (CPT), isolated from the bark of Camptotheca acuminata, is a cytotoxic …

Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

Despite significant advances in the treatment of cervical, ovarian, and uterine cancers with
the approvals of checkpoint and PARP inhibitors into standard treatment, patients with …

Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—
the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells …

Cancer is one of the deadliest diseases, causing million of deaths each year globally.
Conventional anti-cancer therapies are non-targeted and have systemic toxicities limiting …

Antibody–drug conjugates (ADC) using DNA topoisomerase I inhibitor DXd/SN-38 have
transformed cancer treatment, yet more effective ADCs are needed for overcoming …

Over the past few decades, the complexity of molecular entities being advanced for
therapeutic purposes has continued to evolve. A main propellent fueling innovation is the …